Taiwanese Journal of Obstetrics and Gynecology
Volume 44, Issue 3 , Pages 232-241 , September 2005

Human Papillomavirus Vaccine for Cervical Cancer: Where Are We Now?

  • Wen-Fang Cheng

      Affiliations

    • Corresponding Author InformationCorrespondence to: Dr. Wen-Fang Cheng, Department of Obstetrics and Gynecology, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan

Received 28 July 2005 ,Revised 1 August 2005 ,Accepted 4 August 2005.

References 

  1. Harro CD , Pang YY , Roden RB , et al.   Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine . J Natl Cancer Inst . 2001;93:284–292
  2. 2004, W.H.R. Changing History. Statistical annex. World Health Organization, http://www.who.int/whr/2004/en/index.htm
  3. 2000 Cancer Registration Report. Department of Health, Executive Yuan, Taiwan.
  4. Miller AB , Sankaranarayanan R , Bosch FX , Sepulveda C . Can screening for cervical cancer be improved, especially in developing countries? . Int J Cancer . 2003;107:337–340
  5. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses, Volume 64 . Lyon: International Agency for Research on Cancer Press; 1995;
  6. Smith HO , Tiffany MF , Qualls CR , Key CR . The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study . Gynecol Oncol . 2000;78:97–105
  7. Mohar A , Frias-Mendivil M . Epidemiology of cervical cancer . Cancer Invest . 2000;18:584–590
  8. Bosch FX , Manos MM , Munoz N , et al.   Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group . J Natl Cancer Inst . 1995;87:796–802
  9. Wang PD , Lin RS . Epidemiology of cervical cancer in Taiwan . Gynecol Oncol . 1996;62:344–352
  10. Lai MY , Chou P . Effectiveness of screening for cervical cancer in Taiwan. A case-control study . Zhonghua Yi Xue Za Zhi (Taipei) . 1992;49:81–85 [In Chinese]
  11. Lin HH , Cheng WF , Chan KW , Chang DY , Chen CK , Huang SC . Risk factors for recurrence in patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation . Obstet Gynecol . 1996;88:274–279
  12. Chen TM , Chen CA , Wu CC , Huang SC , Chang CF , Hsieh CY . The genotypes and prognostic significance of human papillomaviruses in cervical cancer . Int J Cancer . 1994;57:181–184
  13. Chang TC , Lai CH , Hong JH , et al.   Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer . J Clin Oncol . 2000;18:1740–1747
  14. Rotkin ID . A comparison review of key epidemiological studies in cervical cancer related to current searches for transmissible agents . Cancer Res . 1973;33:1353–1367
  15. Bosch FX , Castellsague X , Munoz N , et al.   Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain . J Natl Cancer Inst . 1996;88:1060–1067
  16. Bosch FX , de Sanjose S . Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality . J Natl Cancer Inst Monogr . 2003;3–13
  17. Bosch FX , Lorincz A , Munoz N , Meijer CJ , Shah KV . The causal relation between human papillomavirus and cervical cancer . J Clin Pathol . 2002;55:244–265
  18. Koskela P , Anttila T , Bjorge T , et al.   Chlamydia trachomatis infection as a risk factor for invasive cervical cancer . Int J Cancer . 2000;85:35–39
  19. Torres Lobaton A , Rojo Herrera G , Torres Rojo A , Hurtado Estrada G , Roman Bassaure E . Cervical cancer. Current view of its epidemiology and risk factors . Ginecol Obstet Mex . 2004;72:466–474 [In Spanish]
  20. Moore MA , Tajima K . Cervical cancer in the Asia Pacific-epidemiology, screening and treatment . Asian Pac J Cancer Prev . 2004;5:349–361
  21. Doll R , Peto R . The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today . J Natl Cancer Inst . 1981;66:1191–1308
  22. Orth G , Jablonska S , Breitburd F , Favre M , Croissant O . The human papillomaviruses . Bull Cancer . 1978;65:151–164
  23. Wu TC . Immunology of the human papilloma virus in relation to cancer . Curr Opin Immunol . 1994;6:746–754
  24. Sedman SA, Barbosa MS, Vass WC, Hubbert NL, Haas JA, Lowy DR, et al. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture . J Virol . 1991;65:4860–4866
  25. von Knebel Doeberitz M , Oltersdorf T , Schwarz E , Gissmann L . Correlation of modified human papilloma virus early gene expression with altered growth properties in C4–1 cervical carcinoma cells . Cancer Res . 1988;48:3780–3786
  26. Halbert CL , Demers GW , Galloway DA . The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells . J Virol . 1992;66:2125–2134
  27. Munger K , Howley PM . Human papillomavirus immortalization and transformation functions . Virus Res . 2002;89:213–228
  28. Halpert R , Fruchter RG , Sedlis A , Butt K , Boyce JG , Sillman FH . Human papillomavirus and lower genital neoplasia in renal transplant patients . Obstet Gynecol . 1986;68:251–258
  29. Schafer A , Friedmann W , Mielke M , Schwartlander B , Koch MA . The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression . Am J Obstet Gynecol . 1991;164:593–599
  30. Laga M , Icenogle JP , Marsella R , et al.   Genital papillomavirus infection and cervical dysplasia-opportunistic complications of HIV infection . Int J Cancer . 1992;50:45–48
  31. Brandsma JL . Animal models for HPV vaccine development . Papillomavirus Report . 1994;5:105–111
  32. Selvakumar R , Schmitt A , Iftner T , Ahmed R , Wettstein FO . Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8+ cells and persistence of viral DNA after regression . J Virol . 1997;71:5540–5548
  33. Suzich JA , Ghim SJ , Palmer-Hill FJ , et al.   Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas . Proc Natl Acad Sci USA . 1995;92:11553–11557
  34. Tagami H , Aiba S , Rokugo M . Regression of flat warts and common warts . Clin Dermatol . 1985;3:170–178
  35. Benton C , Shahidullah H , Hunter JAA . Human papilloma-virus in the immunosuppressed . Papillomavirus Report . 1992;3:23–26
  36. Davies DH , Hill CM , Rothbard JB , Chain BM . Definition of murine T helper cell determinants in the major capsid protein of human papillomavirus type 16 . J Gen Virol . 1990;71:2691–2698
  37. Comerford SA , McCance DJ , Dougan G , Tite JP . Identification of T- and B-cell epitopes of the E7 protein of human papillomavirus type 16 . J Virol . 1991;65:4681–4690
  38. Tindle RW , Fernando GJ , Sterling JC , Frazer IH . A “public” T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes . Proc Natl Acad Sci USA . 1991;88:5887–5891
  39. Steller MA , Gurski KJ , Murakami M , et al.   Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7 . Clin Cancer Res . 1998;4:2103–2109
  40. Altmann A, Jochmus KI, Frank R, Gausepohl H, Moebius U, Gissmann L, et al. Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7 . Eur J Cancer . 1992;28:326–333
  41. Kadish AS, Ho GYF, Burk RD, Wang Y, Romney SL, Ledwidge R, et al. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia . J Natl Cancer Inst . 1997;89:1285–1293
  42. Stauss HJ , Davies H , Sadovnikova E , Chain B , Horowitz N , Sinclair C . Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus . Proc Natl Acad Sci USA . 1992;89:7871–7875
  43. Feltkamp MC , Smits HL , Vierboom MP , et al.   Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells . Eur J Immunol . 1993;23:2242–2249
  44. Sadovnikova E , Stauss HJ . T cell epitopes in human papilloma virus proteins . Behring Inst Mitt . 1994;87–93
  45. Gao L , Chain B , Sinclair C , et al.   Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector . J Gen Virol . 1994;75:157–164
  46. Bauer S , Heeg K , Wagner H , Lipford GB . Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7 . Scand J Immunol . 1995;42:317–323
  47. Kast WM , Brandt RM , Drijfhout JW , Melief CJ . Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2 . J Immunother . 1993;14:115–120
  48. Kast W , Brandt R , Sidney J , et al.   Role of HLA-A motifs in identification of potential CTL epitopes in human papilloma-virus type 16 E6 and E7 proteins . J Immunology . 1994;152:3904–3912
  49. Tarpey I, Stacey S, Hickling J, Birley H, Renton A, McIndoe A, et al. Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2(A*0201) motif . Immunology . 1994;81:222–227
  50. Ressing ME , Sette A , Brandt RM , et al.   Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides . J Immunol . 1995;154:5934–5943
  51. Borysiewicz LK , Fiander A , Nimako M , et al.   A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer . Lancet . 1996;347:1523–1527
  52. Ressing ME , van Driel WJ , Celis E , et al.   Occasional memory cytotoxic T-cell responses of patients with human papilloma-virus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope . Cancer Res . 1996;56:582–588
  53. Evans C , Bauer S , Grubert T , et al.   HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions . Cancer Immunol Immunother . 1996;42:151–160
  54. Nakagawa M , Stites DP , Farhat S , et al.   Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia . J Infect Dis . 1997;175:927–931
  55. Evans EM , Man S , Evans AS , Borysiewicz LK . Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes . Cancer Res . 1997;57:2943–2950
  56. Cubie HA , Norval M , Crawford L , Banks L , Crook T . Lymphoproliferative response to fusion proteins of human papillomaviruses in patients with cervical intraepithelial neoplasia . Epidemiol Infect . 1989;103:625–632
  57. Charleson FC , Norval M , Benton EC , Hunter JA . Lymphoproliferative responses to human papillomaviruses in patients with cutaneous warts . Br J Dermatol . 1992;127:551–559
  58. Strang G, Hickling JK, McIndoe GA, Howland K, Wilkinson D, Ikeda H, et al. Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: identification of T cell determinants, HLA-DR restriction and virus type specificity . J Gen Virol . 1990;71:423–431
  59. Steele JC , Stankovic T , Gallimore PH . Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein . J Virol . 1993;67:2799–2806
  60. Kadish AS , Romney SL , Ledwidge R , et al.   Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific . J Gen Virol . 1994;75:2277–2284
  61. de Gruijl TD , Bontkes HJ , Stukart MJ , et al.   T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia with a persistent viral infection . J Gen Virol . 1996;77:2183–2191
  62. Shepherd PS , Rowe AJ , Cridland JC , Coletart T , Wilson P , Luxton JC . Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia . J Gen Virol . 1996;77:593–602
  63. Shepherd PS, Tran TT, Rowe AJ, Cridland JC, Comerford SA, Chapman MG, et al. T cell responses to the human papillomavirus type 16 E7 protein in mice of different haplotypes . J Gen Virol . 1992;73:1269–1274
  64. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4 . Science . 1991;254:713–716
  65. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosine gene . Proc Natl Acad Sci USA . 1994;91:9461–9465
  66. Topalian SL , Rivoltini L , Mancini M , Ng J , Hartzman RJ , Rosenberg SA . Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells . Int J Cancer . 1994;58:69–79
  67. Ostrand-Rosenberg S , Thakur A , Clements V . Rejection of mouse sarcoma cells after transfection of MHC class II genes . J Immunol . 1990;144:4068–4071
  68. James RF , Edwards S , Hui KM , Bassett PD , Grosveld F . The effect of class II gene transfection on the tumorigenicity of the H-2K-negative mouse leukaemia cell line K36.16 . Immunology . 1991;72:213–218
  69. Chen PW , Ananthaswamy HN . Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2 . J Immunol . 1993;151:244–255
  70. Tew JG , Kosco MH , Burton GF , Szakal AK . Follicular dendritic cells as accessory cells . Immunol Rev . 1990;117:111–185
  71. Sprent J . T and B memory cells . Cell . 1994;76:315–322
  72. Kataja V , Syrjanen S , Yliskoski M , et al.   Risk factors associated with cervical human papillomavirus infections: a case-control study . Am J Epidemiol . 1993;138:735–745
  73. Feldman JG , Chirgwin K , Dehovitz JA , Minkoff H . The association of smoking and risk of condyloma acuminatum in women . Obstet Gynecol . 1997;89:346–350
  74. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, et al. Molecular characterization of defective antigen processing in human prostate cancer . J Natl Cancer Inst . 1995;87:280–285
  75. Vegh Z , Wang P , Vanky F , Klein E . Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors . Cancer Res . 1993;53:2416–2420
  76. Ryu KS , Lee YS , Kim BK , et al.   Alterations of HLA class I and II antigen expression in preinvasive, invasive and metastatic cervical cancers . Exp Mol Med . 2001;33:136–144
  77. Serrano A , Brady CS , Jimenez P , et al.   A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells . Immunogenetics . 2000;51:1047–1052
  78. Koopman LA , Corver WE , van der Slik AR , Giphart MJ , Fleuren GJ . Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer . J Exp Med . 2000;191:961–976
  79. Koopman LA , van Der Slik AR , Giphart MJ , Fleuren GJ . Human leukocyte antigen class I gene mutations in cervical cancer . J Natl Cancer Inst . 1999;91:1669–1677
  80. Connor ME , Stern PL . Loss of MHC class-I expression in cervical carcinomas . Int J Cancer . 1990;46:1029–1034
  81. Cromme FV , Airey J , Heemels MT , et al.   Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas . J Exp Med . 1994;179:335–340
  82. Cromme F , Meijer C , Snijders P , et al.   Analysis of MHC Class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions . Br J Cancer . 1993;67:1372–1980
  83. Walboomers JM , Jacobs MV , Manos MM , et al.   Human papillomavirus is a necessary cause of invasive cervical cancer worldwide . J Pathol . 1999;189:12–19
  84. Winer RL , Lee SK , Hughes JP , Adam DE , Kiviat NB , Koutsky LA . Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students . Am J Epidemiol . 2003;157:218–226
  85. Franco EL , Duarte-Franco E , Ferencz A . Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection . CMAJ . 2001;164:1017–1025
  86. Franco EL , Harper DM . Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control . Vaccine . 2005;23:2388–2394
  87. Munoz N , Bosch FX , de Sanjose S , et al.   Epidemiologic classification of human papillomavirus types associated with cervical cancer . N Engl J Med . 2003;348:518–527
  88. Zielinski GD , Snijders PJ , Rozendaal L , et al.   HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears . Br J Cancer . 2001;85:398–404
  89. Cheng WF , Hung CF , Chen CA , et al.   Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis . Vaccine . 2005;23:3864–3874
  90. Cheng WF, Hung CF, Pai SI, Hsu KF, He L, Ling M, et al. Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects . J Biomed Sci . 2002;9:675–687
  91. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen . J Clin Invest . 2001;108:669–678
  92. Munoz N . Human papillomavirus and cancer: the epidemiological evidence . J Clin Virol . 2000;19:1–5
  93. Goldie SJ , Grima D , Kohli M , Wright TC , Weinstein M , Franco E . A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine . Int J Cancer . 2003;106:896–904
  94. Kang M , Lagakos SW . Evaluating the role of human papillomavirus vaccine in cervical cancer prevention . Stat Methods Med Res . 2004;13:139–155
  95. Muderspach L , Wilczynski S , Roman L , et al.   A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive . Clin Cancer Res . 2000;6:3406–3416
  96. Ault KA , Giuliano AR , Edwards RP , et al.   A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine . Vaccine . 2004;22:3004–3007
  97. Harper DM , Franco EL , Wheeler C , et al.   Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial . Lancet . 2004;364:1757–1765
  98. Villa LL , Costa RL , Petta CA , et al.   Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial . Lancet Oncol . 2005;6:271–278
  99. Koutsky LA , Ault KA , Wheeler CM , et al.   A controlled trial of a human papillomavirus type 16 vaccine . N Engl J Med . 2002;347:1645–1651
  100. Evans TG , Bonnez W , Rose RC , et al.   A Phase 1 study of a recombinant virus-like particle vaccine against human papillomavirus type 11 in healthy adult volunteers . J Infect Dis . 2001;183:1485–1493
  101. Emeny RT , Wheeler CM , Jansen KU , et al.   Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine . J Virol . 2002;76:7832–7842
  102. Pinto LA , Edwards J , Castle PE , et al.   Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles . J Infect Dis . 2003;188:327–338
  103. Muller M , Zhou J , Reed TD , et al.   Chimeric papillomavirus-like particles . Virology . 1997;234:93–111
  104. Greenstone HL , Nieland JD , de Visser KE , et al.   Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model . Proc Natl Acad Sci USA . 1998;95:1800–1805
  105. Hines JF, Ghim SJ, Christensen ND, Kreider JW, Barnes WA, Schlegel R, et al. The expressed L1 proteins of HPV-1, HPV-6, and HPV-11 display type-specific epitopes with native conformation and reactivity with neutralizing and nonneutralizing antibodies . Pathobiology . 1994;62:165–171
  106. Christensen ND , Kreider JW , Cladel NM , Galloway DA . Immunological cross-reactivity to laboratory-produced HPV-11 virions of polysera raised against bacterially derived fusion proteins and synthetic peptides of HPV- 6b and HPV-16 capsid proteins . Virology . 1990;175:1–9
  107. Roden RB , Yutzy WH , Fallon R , Inglis S , Lowy DR , Schiller JT . Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes . Virology . 2000;270:254–257
  108. Dupuy C , Buzoni-Gatel D , Touze A , Bout D , Coursaget P . Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes . J Virol . 1999;73:9063–9071
  109. Liu Y, Chiriva-Internati M, Grizzi F, Salati E, Roman JJ, Lim S, et al. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector . Cancer Gene Ther . 2001;8:948–957
  110. Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M, et al. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen . J Immunol . 2001;166:5733–5740
  111. Hung CF, Cheng WF, He L, Ling M, Juang J, Lin CT, et al. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes . Cancer Res . 2003;63:2393–2398
  112. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, et al. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen . Cancer Res . 2001;61:3698–3703
  113. Hung CF, Hsu KF, Cheng WF, Chai CY, He L, Ling M, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand . Cancer Res . 2001;61:1080–1088
  114. Cheng WF , Hung CF , Lin KY , et al.   CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with down-regulated MHC class I expression by DNA vaccination . Gene Ther . 2003;10:1311–1320
  115. de Jong A , O'Neill T , Khan AY , et al.   Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine . Vaccine . 2002;20:3456–3464
  116. Hallez S , Simon P , Maudoux F , et al.   Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia . Cancer Immunol Immunother . 2004;53:642–650
  117. Ferrara A , Nonn M , Sehr P , et al.   Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients . J Cancer Res Clin Oncol . 2003;129:521–530
  118. Kawana K , Yasugi T , Kanda T , et al.   Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers . Vaccine . 2003;21:4256–4260

PII: S1028-4559(09)60145-5

doi: 10.1016/S1028-4559(09)60145-5

Taiwanese Journal of Obstetrics and Gynecology
Volume 44, Issue 3 , Pages 232-241 , September 2005

Article Tools